The Blood Coagulation drugs in development market research report provides comprehensive information on the therapeutics under development for Blood Coagulation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Blood Coagulation. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Blood Coagulation and features dormant and discontinued products.
GlobalData tracks 17 drugs in development for Blood Coagulation by 14 companies/universities/institutes. The top development phase for Blood Coagulation is discovery with six drugs in that stage. The Blood Coagulation pipeline has 17 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Blood Coagulation pipeline products market are: Korea United Pharm, Aptahem and VarmX.
The key targets in the Blood Coagulation pipeline products market include 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase (HMG CoA Reductase or Hydroxymethylglutaryl CoA Reductase or HMGCR or EC 1.1.1.34), Angiotensin Converting Enzyme (Dipeptidyl Carboxypeptidase I or Kininase II or CD143 or ACE or EC 3.4.15.1 or EC 3.2.1.), and Coagulation Factor VII (Proconvertin or Serum Prothrombin Conversion Accelerator or SPCA or Eptacog Alfa or F7 or EC 3.4.21.21).
The key mechanisms of action in the Blood Coagulation pipeline product include 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase (HMG CoA Reductase or Hydroxymethylglutaryl CoA Reductase or HMGCR or EC 1.1.1.34) Inhibitor with two drugs in Phase III. The Blood Coagulation pipeline products include five routes of administration with the top ROA being Oral and six key molecule types in the Blood Coagulation pipeline products market including Small Molecule, and Recombinant Protein.
Blood Coagulation overview
Blood Coagulation, also known as clotting, is the process by which blood changes from a liquid to a gel, forming a blood clot. It potentially results in hemostasis, the cessation of blood loss from a damaged vessel, followed by repair. The mechanism of coagulation involves activation, adhesion and aggregation of platelets, as well as deposition and maturation of fibrin.
For a complete picture of Blood Coagulation’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
